ActRII Signaling Modulation for Cell Adhesion and Metastasis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic cancers are ineffective, and the signaling pathways that promote cell detachment and metastasis are largely unknown, making it difficult to develop agents that inhibit cell migration and promote cell adhesion.
Innovation Solution
The development of methods and kits to identify agents that modulate ActRII signaling and associated disintegrins to inhibit cell detachment and increase cell attachment, using techniques such as oligonucleotides and antibodies to suppress ActRII signaling and measure changes in cell detachment and adhesion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for metastatic cancers are used, then existing therapy protocols are maintained, but treatment effectiveness is insufficient
Solution Approach 1:
The patent changes the molecular signaling parameters by targeting the ActRII pathway and associated disintegrins (ADAM-15, ADAM17/18), shifting from conventional cancer therapy parameters to pathway-specific molecular parameters. This enables identification of agents that modulate cell adhesion and migration through specific signaling pathway intervention.
Solution Approach 2:
The patent introduces ActRII signaling pathway components as intermediaries between conventional treatments and cancer cells. By using oligonucleotides and antibodies that suppress ActRII signaling, the invention creates a mediating mechanism that controls cell detachment and metastasis through this specific pathway.
2Reliability
If signaling pathways promoting cell detachment are targeted, then cell adhesion is improved, but the complexity of identifying effective agents increases
Solution Approach 1:
The patent segments the complex metastasis process into distinct measurable components: cell detachment, cell adhesion, and migration. By creating separate assay components for each function, the complex biological process is divided into manageable testing modules that can be systematically evaluated.
Solution Approach 2:
The patent develops a multi-functional assay system that can simultaneously evaluate cell detachment, adhesion, and migration using the ActRII pathway as a common target. This universal approach allows a single assay platform to test multiple aspects of metastasis through one signaling pathway.
Data Source
AI summary
Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility.